<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858893</url>
  </required_header>
  <id_info>
    <org_study_id>CoMDA</org_study_id>
    <nct_id>NCT04858893</nct_id>
  </id_info>
  <brief_title>Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms</brief_title>
  <acronym>CoMDA-ML-P</acronym>
  <official_title>Cognitive Screening in Patients With Parkinsonism: Proposal for a New, Machine Learning Based Diagnostic Tool</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Generale Di Zona Moriggia-Pelascini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale di Vipiteno-Sterzing (SABES-ASDAA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale Generale Di Zona Moriggia-Pelascini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on a prospectively collected data analysis, a new tool, namely CoMDA (Cognition in&#xD;
      Movement Disorders Assessment) is developed by merging each item of Mini-Mental State&#xD;
      Examination (MMSE), Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery&#xD;
      (FAB). A machine learning, able to classify the cognitive profile and predict patients' at&#xD;
      risk of dementia, is created.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospectively data-base was setting up, collecting CoMDA and&#xD;
      in-depht-neuropsychologocal-battery scores, obtained from the evaluation of 500 patients with&#xD;
      parkinsonisms. Data were analyzed to compare the classification of patient cognition profile,&#xD;
      obtained with CoMDA, MMSE, MoC and FAB, with that obtained from in-depth neuropsychological&#xD;
      evaluation. A very high percentage of false negative emerged, for MMSE, MoCA and FAB.&#xD;
      Conversely, the CoMDA score significantly reduces the rate of false negative.&#xD;
&#xD;
      This new tool, namely &quot;CoMDA&quot; (Cognition in Movement Disorders Assessment), was composed, by&#xD;
      merging each item of Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment&#xD;
      (MoCA) and Frontal Assessment Battery (FAB). Moreover, we created a machine learning, namely&#xD;
      &quot;Neural Net 91classification&quot; able to classify the cognitive profile and predict patients' at&#xD;
      risk of dementia, providing a prediction of the findings resulting from a in-depht&#xD;
      neuropsychological evaluation.&#xD;
&#xD;
      CoMDA and the related Neural Net 91classification represent a reliable, time-sparing&#xD;
      screening instrument, which is much more powerful of other common, widely-adopted tools.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neural Net 91 classificator from CoMDA score</measure>
    <time_frame>30 minuts</time_frame>
    <description>prediction of cognitive level obtained from the application of Neural Net 91 classificator at CoMDA score</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">562</enrollment>
  <condition>Primary Parkinsonism</condition>
  <condition>Secondary Vascular Parkinson Disease</condition>
  <condition>Multiple System Atrophy</condition>
  <condition>Supranuclear Palsy, Progressive</condition>
  <arm_group>
    <arm_group_label>Subjects affected from Parkinsonims</arm_group_label>
    <description>Scores of MMSE, FAB MoCA were summarized to calculate the CoMDA scores, than they were used to develop the Neural Net 91 classificator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Controls</arm_group_label>
    <description>CoMDA was administered and total score was calculate to develop the Neural Net 91 classificator</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CoMDA associated with Neural Net 91 classificator</intervention_name>
    <arm_group_label>Health Controls</arm_group_label>
    <arm_group_label>Subjects affected from Parkinsonims</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        500 subjects suffering from different forms of Parkinson Disease or Atypical Parkinsonims&#xD;
        Syndorme and 61 Helathy Controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        diagnosis of idiopathic PD according to the MDS clinical diagnostic criteria (Postuma et&#xD;
        al. 2015); b) diagnosis of PSP according to the MDS clinical diagnostic criteria (Höglinger&#xD;
        et al. 2017); c) diagnosis of MSA according to the second diagnostic consensus statement&#xD;
        (Gilman et al. 2008); d) diagnosis of VP according to Zijlmans et al (Zijlmans et al.&#xD;
        2004).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        a) any focal brain lesion detected with brain imaging studies (CT or MRI); b) diagnosis of&#xD;
        clinically relevant psychiatric disorders, psychosis (evaluated with Neuropsychiatric&#xD;
        Inventory) and/or delirium; c) diagnosis of dementia or MCI; d) diagnosis of neurological&#xD;
        diseases other than PD or atypical parkinsonian syndromes; e) other medical conditions&#xD;
        negatively affecting the cognitive status; f) disturbing resting and/or action tremor,&#xD;
        corresponding to scores 2-4 in the specific items of MDS Unified Parkinson's Disease Rating&#xD;
        Scale (MDS-UPDRS) III, such as to affect the psychometric evaluation; g) disturbing&#xD;
        dyskinesia, corresponding to scores 2-4 in the specific items of MDS-UPDRS III, such as to&#xD;
        affect the psychometric evaluation; h) auditory and/or visual dysfunctions impairing the&#xD;
        patient´s ability to perform cognitive tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>&quot;Moriggia Pelascini&quot; Hospital</name>
      <address>
        <city>Gravedona E Uniti</city>
        <state>Como</state>
        <zip>22015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Parkinson Disease, Secondary</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

